What additional medication should be included in the care plan for a 71-year-old man with COPD experiencing worsening cough and thicker mucus production?

In patients with Chronic Obstructive Pulmonary Disease (COPD) who experience increased cough and thicker mucus production, incorporating a long-acting muscarinic antagonist into the care plan can be particularly beneficial for several reasons.

Long-acting muscarinic antagonists (LAMAs) work by blocking the action of acetylcholine on muscarinic receptors in the airway, leading to bronchodilation and reduced mucus secretion. This reduces airway resistance and improves airflow, which is essential for patients with COPD. Additionally, LAMAs have been shown to improve lung function and may reduce the frequency of COPD exacerbations, providing symptomatic relief and enhancing the overall quality of life for patients. The mechanism of action not only promotes bronchodilation but also helps address issues associated with mucus production, making it a relevant choice for a patient with worsening cough and thicker mucus.

The other medication options, while relevant to COPD management, do not directly address the combination of thick mucus and cough in the same effective manner as a LAMA. For instance, short-acting beta-agonists are effective for quick relief of bronchospasm but may not have the same prolonged effect as LAMAs. Corticosteroids, while useful for reducing inflammation, can have systemic side